News
Article
AJMC® in the Press, October 25, 2024
Author(s):
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article from Healthcare IT Today referenced a study published in the May 2024 Health Information Technology special issue of The American Journal of Managed Care® (AJMC®). The study, “Interventional Analytics in Skilled Nursing Facilities Associated With Reduced Readmissions,” found that skilled nursing facilities that implemented an interventional analytics platform had statistically and clinically significant superior risk-adjusted readmission rates.
A study published in the September 2024 issue of AJMC, “When is a Network Adequate? Consumer Perspectives on Network Adequacy Definitions,” was referenced in an article from MedicalXpress. The study polled consumers about their conceptions of network adequacy, with most consumers supportive of standard definitions of adequacy that focused on the travel distance and the number of providers in their area.
An article from MedPage Today referenced a study published in the March 2024 issue of AJMC. The study, “The Extent and Growth of Prior Authorization in Medicare Advantage,” found that about 3 in 4 enrollees in Medicare Advantage had a plan that required prior authorization, with some area-level demographic and provider market characteristics associated with prior authorization requirements.
An article from UPI referenced an FDA approval news item published on AJMC.com, the website of AJMC. The article, “FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B,” featured an FDA decision on marstacimab, which reduced annualized bleeding rates by 35% compared with prophylaxis and 92% compared with on-demand treatment in patients with hemophilia B.
An article from Pharmacy Times referenced an article published by AJMC®’s sister site, The Center for Biosimilars. The article, “Phase 3 Trials Find Subcutaneous Infliximab CT-P13 Superior to Placebo in IBD,” reported on the phase 3 results for infliximab in patients living with inflammatory bowel disease, with 62% of those receiving CT-P13 achieving clinical remission.
